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ABSTRACT
Objective: To evaluate the applicability of the incremental (shuttle) walk test in patients with chronic obstructive
pulmonary disease and compare the performance of those patients on the shuttle walk test to that of the same patients
on the encouraged 6-minute walk test. Methods: A cross-sectional study was conducted, in which 24 patients with
chronic obstructive pulmonary disease were selected. In random order, patients were, after an initial practice period,
submitted to a shuttle walk test and an encouraged 6-minute walk test. Results: The patients obtained a higher heart
rate (expressed as a percentage of that predicted based on gender and age) on the encouraged 6-minute walk test (84.1
± 11.4%) than on the shuttle walk test (76.4 ± 9.7%) (p = 0.003). The post-test sensation of dyspnea (Borg scale) was
also higher on the encouraged 6-minute walk test. On average, the patients walked 307.0 ± 89.3 meters on the shuttle
walk test and 515.5 ± 102.3 meters on the encouraged 6-minute walk test (p < 0.001). There was a good correlation
between the two tests in terms of the distance walked (r = 0.80, p < 0.001). Conclusion: The shuttle walk test is simple
and easy to implement in patients with chronic obstructive pulmonary disease. The encouraged 6-minute walk test
produced higher post-test heart rate and greater post-test sensation of dyspnea than did the shuttle walk test.
Keywords: Pulmonary disease, chronic obstructive/rehabilitation; Exercise test; Motor activity; Reproducibility of results;
Walking; Exercise tolerance
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD)
is characterized by the chronic presence of
symptoms such as cough and sputum production
and, in more advanced cases, dyspnea (upon
exertion or at rest), all caused by changes in
pulmonary mechanics and gas exchange, as well
as by a reduction in skeletal muscle aerobic
capacity.(1) To date, except for smoking cessation,
there have been no therapeutic means of altering
the progressive functional decline in forced
expiratory volume in one second, which is a
pronounced aspect of this disease.(1) However, there
are other factors, such as dyspnea, quality of life,
nutritional state and exercise tolerance, that can
be improved through intervention.(2) One popular
program of pulmonary rehabilitation is based on
an ample group of interventions, chief among
which is an intervention based on the evaluation
and improvement of physical capacity by means
of a physical training program.(1)
Despite the increasing numbers of pulmonary
rehabilitation centers in Latin America,(3) the
foundation of evaluation and physical training of
COPD patients submitted to pulmonary rehabilitation
is still accompanied by the use of complex, costly
equipment that can only be operated by specialized
personnel. For example, cardiopulmonary exercise
testing is combined with direct determination of
peak or maximal oxygen consumption and the
determination of the anaerobic threshold, all used
for designing a physical exercise program.(4-6)
Therefore, in order to facilitate the evaluation of
the physical capacity of patients and reduce the costs
of a pulmonary rehabilitation program, inexpensive
field tests that can be easily carried out have been
developed. Such tests include the six-minute walk
test (6MWT),(7) step test(8) and incremental walk test,
also known as the shuttle walk test (SWT).(9)
The SWT is considered a maximal incremental
test since patients are induced to walk at
standardized, increasing speeds, at twelve different
levels, each lasting one minute with the help an
auditory cue used to control pace on a ten-meter
shuttle circuit delineated by two traffic cones. The
test should be carried out until the point of
exhaustion (Chart 1). The SWT is simple, with good
reproducibility, and is based on walking on any flat
surface; it requires no specific ergometers;(9-10) it is
used as an outcome measure in the evaluation of
various interventions used for COPD patients.(9,11-14)
Regarding exercise tolerance, this test has shown
good correlation between the walking distance and
peak oxygen consumption at the end of the test (r
= 0.81), which is similar to that obtained in maximal
treadmill stress tests (r = 0.88).(15) Peak oxygen
consumption at the end of the SWT has a correlation
of 0.71 when compared to that obtained using a
cycle ergometer.(6) To the best of our knowledge,
there have been no studies evaluating the
applicability of the SWT in Brazil.
In contrast, the 6MWT is the most commonly
used test and is a component of the multidimensional
index. In addition, it is a better predictor of mortality
in COPD patients than is forced expiratory volume
in one second.(2) The 6MWT is considered a
submaximal test since patients are instructed to walk
at the highest speed tolerated for six minutes,
motivated through standardized verbal
encouragement. Therefore, during its performance,
the 6MWT depends on individually adjusted
characteristics, which are determined by the
patients, who may even stop walking if they wish
to. Variability is higher on the 6MWT than on the
SWT, but the two present similar correlations with
peak oxygen consumption (r = 0.73).(7) A variation
of the 6MWT was developed at the Pulmonary
Rehabilitation Center of the Federal University of
São Paulo.(16) In this modified 6MWT, a professional
(physician or physical therapist) encourages patients
Chart 1 - Levels in the incremental walk test and
their respective speed, together with the number of
shuttles per level and time per shuttle
 Level     Speed        # shuttles per       Time per
         m/s    mph          level         shuttle seconds
  1 0.50 1.12 3 20"
  2 0.67 1.50 4 15"
  3 0.84 1.88 5 12"
  4 1.01 2.26 6 10"
  5 1.18 2.64 7 8"57
  6 1.35 3.02 8 7"50
  7 1.52 3.40 9 6"66
  8 1.69 3.78 10 6"
  9 1.86 4.16 11 5"45
 10 2.03 4.54 12 5"
 11 2.20 4.92           13 4"61
 12 2.37 5.30 14 4"28
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by walking ahead of them, imposing a certain speed
that must be maintained for six minutes. This test
has been designated the encouraged six-minute walk
test (E6MWT).(16) In the E6MWT, patients can be
led to maintain maximum walking speed throughout
the test, approximating the performance achieved
on a maximal test.
The objective of this study was to evaluate the
applicability of the SWT in COPD patients and, based
on the characteristics of the SWT and the E6MWT -
low cost and ease of implementation - to compare
the two tests in terms of COPD patient performance.
METHODS
A cross-sectional descriptive study was
conducted. A total of 24 consecutive patients with
COPD(1) were selected from among patients treated
at the COPD clinic of the Pulmonary Rehabilitation
Center of the Federal University of São Paulo.
Inclusion criteria were arterial oxygen tension =
55 mmHg or arterial oxygen saturation by pulse
oximetry (SpO2) = 92% (at rest and on room air), as
well as at least 6 weeks of clinical stability and
satisfactory ability to walk unaided. Patients with
SpO2 = 80% during exercise were excluded, as were
those suffering from other pulmonary diseases, heart
diseases, cardiac insufficiency or other comorbidities
considered uncontrolled or significant, as well as
those presenting formal contraindications for
performing exercise tests. All patients were submitted
to an incremental cardiopulmonary test on a
treadmill in accordance with Harbor's protocol, with
no oxygen supplementation, in order to rule out
active coronary disease, exercise-induced
arrhythmias or abnormal blood pressure responses.(17)
All patients were submitted to spirometry. A KoKo
spirometer (Pulmonary Data Service Instrumentation,
Inc., Louisville, KY, USA) was used in accordance
with the criteria established by the American
Thoracic Society.(18) In addition, all patients were
submitted to arterial blood gas analysis as well as
to respiratory muscle strength determination using
a vacuum manometer (IMEBRÁS, Sâo Paulo, Brazil).
Body mass index was obtained by calculating the
ratio between weight (kg) and height (m2).
The SWT was carried out in accordance with
the standards described in the literature,(9) which
require patients to walk in a level corridor on a 10-
meter shuttle course. Walking from one end to the
other was considered one ‘shuttle', and returning
was considered another. The distance was delineated
by two traffic cones placed half a meter prior to the
end of each shuttle in order to avoid forcing patients
to make abrupt direction changes (Figure 1).
Walking speed was determined by an auditory cue
indicating when patients were supposed to be by
the cone and change direction and, consequently,
the rhythm was also altered. The auditory cues were
previously recorded on a cassette tape. Instructions
for patients were standardized, and they were able
to listen to the cassette tape prior to the beginning
of the test. Patients were advised: "walk at a steady
pace, aiming to be next to one of the cones and
change directions when you hear the audio signal;
you should keep walking until you feel that you are
no longer able to maintain the required speed".
Heart rate (HR), respiratory frequency, arterial blood
pressure and SpO2 were determined at the end of
the test with patients at rest. Throughout the test,
HR was constantly monitored by means of telemetry
(Polar Electro Oy, Kempele, Finland), and SpO2 by
means of a pulse oximeter. The modified Borg scale
was used in order to quantify the perception of
dyspnea and lower limb fatigue, at rest and after
maximum exercise. The following criteria were
applied for the discontinuation of the SWT: dyspnea
or fatigue preventing the patient from maintaining
the required speed (being at a distance equal to or
greater than three meters from the cones when the
auditory cue for changing directions sounded).
All patients performed one to two E6MWT and
SWT practice sessions prior to the tests themselves
in order to nullify the learning effect and to become
familiar with the differences between the two tests.
The E6MWT was carried out in a 28-meter corridor
and was monitored by a physiotherapist or a
physician who walked ahead of the patient during
the test in order to try to impose maximum walking
speed for six minutes. There was no oxygen
supplementation, and the minimum SpO2 was 80%
for both tests. The two tests were carried out on
the same day, in random order. There was an interval
of at least 30 minutes between tests. When
necessary, this interval was extended to allow
cardiovascular and ventilatory variables to return
to baseline levels. For each patient, HR was
continuously monitored through telemetry and
oximetry. Respiratory frequency, dyspnea and lower
limb fatigue (Borg scale) and arterial blood pressure
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were determined at rest and immediately after the
tests. The distance walked was recorded after the
tests.
We used the Saint George's Respiratory
Questionnaire (SGRQ), previously validated in
Brazil,(19) and Mahler baseline dyspnea index(20) to
evaluate quality of life.
The ethics research committee approved the
protocol, and all patients gave written informed
consent.
Results are expressed as means and standard
deviations. We used the Wilcoxon test to analyze
the differences between the SWT and the E6MWT.
The Spearman correlation coefficient was used to
determine the associations between continuous
variables. Non-parametric tests were justified using
the Kolmogorov-Smirnov test. Sample size had an 80%
power to detect a 10-meter difference in the SWT
(estimating an 11-meter standard deviation),(21-22)
assuming an alpha error of 0.05. We used the SPSS
program, version 10.0, to make the statistical analysis.
RESULTS
Demographic data, as well as pulmonary function
data, for the 24 patients (17 males) with COPD are
shown in Table 1. Mean age was 67.8 ± 7.5 years
(range, 55-84 years), and mean body mass index
was 24.2 ± 4.2 kg/m2. According to the Global
Initiative for Chronic Obstructive Lung Disease
criteria,(1) 2 patients (8.3%) had stage 1 (mild) COPD,
7 (29.2%) had stage 2 (moderate) COPD, 12 (50%)
had stage 3 (severe) COPD, and 3 (12.5%) had stage
4 or higher (extremely severe) COPD. Two patients
(8.3%) presented hypercapnia (arterial carbon
dioxide tension > 45 mmHg). According to the
percentage data (mean ± standard deviation)
obtained from the SGRQ, all patients presented altered
quality of life: Symptoms domain, 58.18 ± 19.23;
Impact domain, 39.94 ± 23.61; Activity domain, 61.94
± 21.64; total score, 49.60 ± 20.15. The mean Mahler
baseline dyspnea index was 7.5 ± 2.1.
Baseline values on both tests were similar for
the following variables: sensation of dyspnea and
lower limb fatigue (Borg), systolic arterial pressure,
diastolic arterial pressure, HR, SpO2 and respiratory
frequency (data not shown). After the E6MWT,
patients presented higher HR and sensation of
dyspnea than after the SWT (p < 0.001 and p =
0.003, respectively, for the two variables). There
were no statistically significant post-test differences
in any of the other parameters (Table 2).
We compared maximum HR obtained during
both tests to the maximum predicted values for
age and gender (males: 211 - 0.87*years of age;
females: 212 - 0.89*years of age).(23) On average,
patients presented 76.1 ± 9.8% of maximum
predicted values after the SWT, which was lower
than the 83.8 ± 11.6% presented after the E6MWT
(p = 0.003). When the same parameters were
compared to the maximum HR attained on the
incremental treadmill test, which was lower than
the predicted value according to age, we found,
on average, 85.6 ± 9.7% for the SWT and 94.0 ±
9.1% for the E6MWT. In both situations, the
difference (higher HR values after the E6MWT) was
statistically significant (p = 0.004). It is of note
that mean HR on the incremental treadmill test
was lower than that predicted for the age (137.2
± 15.9 bpm versus 152.6 + 8.4 bpm, respectively;
p < 0.001).
No complications (indisposition, syncope, chest
pain or any other symptoms, as spontaneously
reported by patients) occurred during the tests.
On average, patients walked 307.0 + 89.3
meters on the SWT and 515.5 ± 102.3 meters on
the E6MWT (p < 0.001). There was a good
TABLE 1
Demographic and pulmonary function data for the 24
patients with chronic obstructive pulmonary disease
Variable                                      Mean +  SD
Age (years) 67.8 + 7.5
BMI (kg/m2) 24.2 + 4.2
FVC (%)* 80.9 + 21.0
FEV1 (%)* 48.6 + 21.0
FEV1/FVC (%)* 45.6 + 9.8
MVV (L/min) 48.5 + 23.4
PaO2 (mmHg) 68.1 + 8.5
PaCO2 (mmHg) 38.9 + 4.8
SaO2 (%) 93.2 + 2.4
MIP (mmHg) -63.3 + 23.5
MEP (mmHg) 111.0 + 28.6
SD: standard deviation; BMI: body mass index; FVC: forced
vital capacity; FEV1: forced expiratory volume in one
second; MVV: maximum voluntary ventilation; PaO2:
arterial oxygen tension; PaCO2: arterial carbon dioxide
tension; SaO2: arterial oxygen saturation; MIP: maximum
inspiratory pressure; MEP: maximum expiratory pressure
*Postbronchodilator
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correlation between the two tests in terms of the
distance walked (r = 0.81, p < 0.001).
In order to compare the construction validity
properties between the tests, we calculated the
correlation coefficients between the various
functional and nutritional variables, as well as those
related to quality of life, symptoms and respiratory
muscle strength. The results are shown in Table 3.
DISCUSSION
A recent study showed that the multidimensional
evaluation of COPD can provide better information
regarding survival, morbidity and mortality when
compared to that provided by evaluations of forced
expiratory volume in one second.(2) In COPD
patients, a great deal of information is obtained
from the study of exercise tolerance, which can,
in isolation, be considered a predictive factor for
mortality.(24) The SWT and the 6MWT are both
inexpensive, simple tests. However, they are
probably underutilized in the day-to-day clinical
evaluation of COPD patients in Brazil. To the best
of our knowledge, this was the first study on the
use of the SWT to assess patients diagnosed with
chronic pulmonary disease in Brazil.
TABLE 2
Maximal arterial pressure, respiratory frequency, heart rate, SpO2 and sensation of dyspnea on the
shuttle walk test and encouraged six-minute walk test
Variable (maximum values)            SWT     E6MWT      Mean difference      p
Respiratory frequency (rpm) 31.6 + 5.0   32.4 + 4.3 -0.8 + 3.6     0.27
SpO2 (%) 88.6 + 4.1   87.6 + 3.9  1.0 + 3.7     0.18
Heart rate (bpm) 115.9 + 14.9 127.7 + 17.6 11.8 + 14.1  <0.001
Systolic arterial pressure (mmHg) 156.3 + 19.3 152.5 + 14.5  3.8 + 16.6    0.281
Diastolic arterial pressure (mmHg) 92.5 + 7.9   93.8 + 8.8 -1.3 + 7.4    0.417
Borg dyspnea 2.8 + 1.4    4.4 + 2.7 -1.7 + 2.4    0.003
Borg lower limbs 2.9 + 2.0    3.9 + 2.6 -1.0 + 2.5    0.061
SWT: shuttle walk test; E6MWT: encouraged 6-minute walk test; SpO2: arterial oxygen saturation by pulse oximetry
TABLE 3
Correlations between the SWT and the 6MWT in
terms of functional and nutritional variables, as
well as those regarding quality of life, symptoms
and respiratory muscle force
  SWT (m)     E6MWT (m)
FEV1 % 0.42
* 0.54**
BDI 0.15 0.49*
PaO2 (mmHg) 0.42
* 0.42*
SGRQ Symptoms % 0.07 0.05
SGRQ Activity % -0.06 -0.38
SGRQ Impact % -0.21    -0.50*
SGRQ total score % -0.14 -0.42
MIP (cmH2O) -0.44
* -0.22
MEP (cmH2O) 0.12 0.10
BMI (kg/m2) 0.16 0.20
*p < 0.05; **p < 0.001
BDI: (Mahler) baseline dyspnea index; SWT: shuttle walk
test; E6MWT: encouraged 6-minute walk test; FEV1:
forced expiratory volume in one second; PaO2: arterial
oxygen tension; SGRQ: Saint George's Respiratory
Questionnaire; MIP: maximum inspiratory pressure; MEP:
maximum expiratory pressure; BMI: body mass index
 S
W
T 
(m
)
E6MWT
Figure 1 - Correlation between the SWT and the E6MWT in
terms of the distance walked (Spearman)
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In the present study, the SWT proved to be
easily implemented, requiring only a portable sound
system (for playing the auditory cue), a 10-meter
level corridor of at least 10 meters in length and
one investigator. The standard 6MWT requires a
long free space of 30 meters in length, although it
can range from 20 to 50 meters(7) (in the present
study, the corridor was 28 meters long, which was
considered adequate). However, the length of the
level surface on which the participants walk seems
to have little influence on the results (the shape
of the circuit seems to be more relevant), as was
reported in a study conducted by the National
Emphysema Treatment Trial Research Group.(25)
Two professionals are necessary in order to carry
out the 6MWT, regardless of the standards used
(6MWT or E6MWT). No complications (such as the
incidence of significant symptoms, arrhythmias or
nonphysiological alterations in blood pressure)
were detected in either test, although both were
maximal or close to maximal performance tests,
and SpO2 tolerance was as high as 80%. We
concluded that both tests had good applicability
in this sample of patients. However, it is important
to highlight the fact that all patients, despite
having moderate or severe COPD, were considered
normal in a previous ergometric evaluation, which
was an inclusion criterion for this study.
In our COPD study sample, mean distance
walked on the SWT was 307 meters, higher than
the 195 meters reported in a study carried out by
the authors who developed the test.(9) In another
study conducted by the same group, the mean
distance walked was 375 meters, similar to that
found in the present study.(15) We found a weak
correlation between the distance walked on the
SWT and the forced expiratory volume in one
second (r = 0.42), a value similar to that reported
in a previous study (r = 0.31).(15) It is important to
emphasize that the sample in the original SWT
study included patients diagnosed with various
etiologies causing bronchial obstruction, rather than
COPD patients exclusively.(9)
Since 1997, a change in the type of encouragement
used during the 6MWT has been proposed in order
to increase reproducibility and make the test more
closely approximate the maximum patient effort.(16) In
fact, when we compare the distance walked on the
6MWT by the patients with COPD in this study to that
walked by normal individuals, the mean distance in
both cases is similar - 515 meters and 580 meters,
respectively.(7) The mean distance walked by patients
with moderate to severe COPD ranges from 264 to
403 meters in the literature.(2,26) In a previous study
conducted at our center, 59 patients with COPD (forced
expiratory value in one second, 47.9 ± 16.5%) were
evaluated, and the mean distance walked on the
E6MWT was 499.7 ± 83.6 meters.(27) This showed that
modifying the type of encouragement given during
the 6MWT induced patients to put forth greater effort,
approaching their maximum capacity, during the test.
The hypothesis that both tests induced effort
close to maximum predicted values can be justified
by the post-test analysis of the parameters, most
of which were, from the clinical and statistical
viewpoint, similar, except for the significantly
higher values for dyspnea and HR obtained after
the E6MWT (Table 2). This is confirmed in most
studies in the literature, in which incremental tests
such as the SWT have been shown to induce
greater increases in cardiovascular variables when
compared to the 6MWT.(9-10) In a recent study,
similar results in the cardiovascular parameters were
reported for the SWT and the 6MWT. However,
the study sample was composed of patients with
COPD recovering from exacerbations, and the
unencouraged form of the 6MWT was used. The
similar behavior of physiological variables in that
study was credited to a reduction in exercise tolerance
found in patients with COPD exacerbations.(28) The
findings in the present study are considered unique
since they are related to patients in a stable phase of
the disease. In our study, there was a good correlation
between the SWT and the E6MWT (r = 0.80), better
than those reported in classical studies,(9,11) but
similar to that found in another study (r = 0.85).(28)
Traditionally, the SWT is characterized as an
incremental test that assumes values close to
maximum when compared to maximal incremental
tests using ergometry. Modifying the stimulus
given during the E6MWT might have led patients
to walk at a speed approximating the maximum
for a prolonged period of time (six minutes for
this test). This concept is similar to that known as
critical potency, in which the load tolerated by
patients with moderate to severe COPD during
high-intensity exercise would be limited to the
dynamic ventilatory response.(29) Endurance was
strongly associated with the level of ventilatory
stress, resulting in an increase in the sensation of
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dyspnea.(29) This would explain, therefore, the
finding of higher levels for the sensation of
dyspnea and HR on the E6MWT than on the SWT,
since the latter is an incremental test that is
interrupted immediately after reaching maximum
load, thereby submitting patients to very high
workloads over a shorter period of time. It has
been reported that, three minutes after the
beginning of the 6MWT, patients reach a walking
speed plateau, accompanied by the maximum
sustainable ventilatory level, which is said to be
close to 90% of maximum voluntary ventilation.
It has been shown that, on a 6MWT involving
standardized external encouragement, patients will
assume the maximum sustainable speed.(30)
Based on the principal findings of the present
study, we concluded that the SWT can be used to
evaluate exercise tolerance in patients with COPD
in Brazil. This test in an incremental field test, is
easily performed and requires no sophisticated
equipment. The comparison between the SWT and
the E6MWT showed that both tests present similar
post-test values, although HR and sensation of
dyspnea were higher after the E6MWT. The clinical
implication of the differences between the use of
these two tests, as a proposal for the training load
in more simplified rehabilitation programs, should
be evaluated in future studies, which should also
include a more detailed evaluation of the
differences between the standard 6MWT and the
E6MWT in terms of the metabolic changes
occurring during their performance.
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